ArticleClinical hematology international2023

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.

Torben Plesner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.